Morrison Briggs's Form 4/A amendment
AmendedSyndax Pharmaceuticals IncSNDX · filed Apr 13, 2022
- Accession no.
- 0001562180-22-003383
- Filed
- Apr 13, 2022
- Trade date
- Apr 1-4, 2022
- Filing delay
- 12 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Apr 5, 2022
This filing lists 2 non-derivative transactions and 2 derivative transactions. It carries over 4 transactions from the original filing that it did not restate. Open-market sales total $1.82M. It was filed 12 days after the trade.
This amendment restates part of 0001562180-22-003223 (filed Apr 5, 2022). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Morrison BriggsCIK 0001654430 | Director, Officer (President, Head of R&D) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 1, 2022 | Common Stock | MOption exerciseDisposed | −70,545 | $0.00 | $0 | 0 | Direct | |
| Apr 4, 2022 | Common Stock | MOption exerciseDisposed | −3,128 | $0.00 | $0 | 0 | Direct |
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0001562180-22-003223 (filed Apr 5, 2022).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 1, 2022 | Common Stock | SSaleDisposed | −6,000 | $17.44F2 | −$104,640 | 42,336 | Direct | |
| Apr 1, 2022 | Common Stock | SSaleDisposed | −24,500 | $17.44F3 | −$427,280 | 17,836 | Direct | |
| Apr 1, 2022 | Common Stock | SSaleDisposed | −70,545 | $17.46F4 | −$1,231,715.7 | 17,836 | Direct | |
| Apr 4, 2022 | Common Stock | SSaleDisposed | −3,128 | $18.29F5 | −$57,211.12 | 17,836 | Direct |
Footnotes on the original
The footnotes that the prices of these transactions refer to on the original filing.
- F2
The sale prices ranged from $17.21 to $17.62.
Referenced by the price of 1 transaction in Table I.
- F3
The sale prices ranged from $17.19 to $17.66.
Referenced by the price of 1 transaction in Table I.
- F4
The sale prices ranged from $17.18 to $17.69.
Referenced by the price of 1 transaction in Table I.
- F5
The sale prices ranged from $17.75 to $19.17.
Referenced by the price of 1 transaction in Table I.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The Reporting Person is not reporting any new transactions in this filing. Amendment filed to correct previously filed Form that contained an incorrect option exercise price and expiration date.
Referenced by the price of 2 transactions in Table I.
- F2
This option is fully vested.